FULC vs. ARDX, HROW, SPRY, SDGR, AMPH, VERA, ABCL, ETNB, SNDX, and COGT
Should you be buying Fulcrum Therapeutics stock or one of its competitors? The main competitors of Fulcrum Therapeutics include Ardelyx (ARDX), Harrow (HROW), ARS Pharmaceuticals (SPRY), Schrodinger (SDGR), Amphastar Pharmaceuticals (AMPH), Vera Therapeutics (VERA), AbCellera Biologics (ABCL), 89BIO (ETNB), Syndax Pharmaceuticals (SNDX), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry.
Fulcrum Therapeutics vs. Its Competitors
Ardelyx (NASDAQ:ARDX) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.
In the previous week, Ardelyx had 2 more articles in the media than Fulcrum Therapeutics. MarketBeat recorded 4 mentions for Ardelyx and 2 mentions for Fulcrum Therapeutics. Ardelyx's average media sentiment score of 1.32 beat Fulcrum Therapeutics' score of 1.15 indicating that Ardelyx is being referred to more favorably in the media.
Fulcrum Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -14.60%. Fulcrum Therapeutics' return on equity of -31.05% beat Ardelyx's return on equity.
58.9% of Ardelyx shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 4.8% of Ardelyx shares are held by insiders. Comparatively, 7.0% of Fulcrum Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Fulcrum Therapeutics has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Fulcrum Therapeutics, indicating that it is currently the more affordable of the two stocks.
Ardelyx has a beta of 0.68, meaning that its stock price is 32% less volatile than the S&P 500. Comparatively, Fulcrum Therapeutics has a beta of 2.47, meaning that its stock price is 147% more volatile than the S&P 500.
Ardelyx currently has a consensus price target of $11.50, indicating a potential upside of 88.22%. Fulcrum Therapeutics has a consensus price target of $7.57, indicating a potential upside of 10.05%. Given Ardelyx's stronger consensus rating and higher possible upside, equities research analysts plainly believe Ardelyx is more favorable than Fulcrum Therapeutics.
Summary
Ardelyx beats Fulcrum Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Fulcrum Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for FULC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding FULC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Fulcrum Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:FULC) was last updated on 8/23/2025 by MarketBeat.com Staff
MarketBeat All Access